Literature DB >> 15595363

A study of sensitivity of the sustained attention to response task in patients with schizophrenia.

R C K Chan1, E Y H Chen, E F C Cheung, R Y L Chen, H K Cheung.   

Abstract

The sustained attention to response task (SART), a measure of sustained attention created by Robertson, Manly, Andrade, Baddeley, and Yiend (1997), was administered to 51 patients with schizophrenia and 51 normal controls to provide information on the sensitivity of the measure in this clinical group. Patients with schizophrenia performed significantly worse than the normal controls in correct response, reaction time for correct response, and efficiency estimate of taking account of both the accuracy and speed of movement. Moreover, the patient group was more often correctly classified as defective on the basis of efficiency estimate than the normal controls. These data provide further evidence of the sensitivity of the SART to patients with schizophrenia.

Entities:  

Mesh:

Year:  2004        PMID: 15595363     DOI: 10.1080/13854040490507208

Source DB:  PubMed          Journal:  Clin Neuropsychol        ISSN: 1385-4046            Impact factor:   3.535


  3 in total

1.  Evidence of dysexecutive syndrome in patients with acromegaly.

Authors:  Shaobo Shan; Lingling Fang; Jia Huang; Raymond C K Chan; Guijun Jia; Weiqing Wan
Journal:  Pituitary       Date:  2017-12       Impact factor: 4.107

2.  Deficient sustained attention to response task and P300 characteristics in early Huntington's disease.

Authors:  E P Hart; E M Dumas; R H A M Reijntjes; K van der Hiele; S J A van den Bogaard; H A M Middelkoop; R A C Roos; J G van Dijk
Journal:  J Neurol       Date:  2011-12-06       Impact factor: 4.849

3.  Neurological soft signs and their relationships to neurocognitive functions: a re-visit with the structural equation modeling design.

Authors:  Raymond C K Chan; Ya Wang; Li Wang; Eric Y H Chen; Theo C Manschreck; Zhan-jiang Li; Xin Yu; Qi-yong Gong
Journal:  PLoS One       Date:  2009-12-24       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.